These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22427733)

  • 1. Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy.
    Roberts SM; Bezinover DS; Janicki PK
    Cancer Manag Res; 2012; 4():67-73. PubMed ID: 22427733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of postoperative nausea and vomiting with single intravenous doses of dolasetron mesylate: a multicenter trial. Dolasetron Mesylate PONV Treatment Study Group.
    Kovac AL; Scuderi PE; Boerner TF; Chelly JE; Goldberg ME; Hantler CB; Hahne WF; Brown RA
    Anesth Analg; 1997 Sep; 85(3):546-52. PubMed ID: 9296407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
    Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE
    BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis.
    Tang DH; Malone DC
    Clin Ther; 2012 Feb; 34(2):282-94. PubMed ID: 22296947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative nausea and vomiting after surgery for prognathism: not only a question of patients' comfort. A placebo-controlled comparison of dolasetron and droperidol.
    Piper SN; Röhm K; Boldt J; Kranke P; Maleck W; Seifert R; Suttner S
    J Craniomaxillofac Surg; 2008 Apr; 36(3):173-179. PubMed ID: 18353666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral dolasetron mesylate for prevention of postoperative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group.
    Diemunsch P; Korttila K; Leeser J; Helmers JH; Wilkey B; Navé S; Radke AJ; Hahne WF; Brown RA
    J Clin Anesth; 1998 Mar; 10(2):145-52. PubMed ID: 9524901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous dolasetron for the prevention of postoperative nausea and vomiting after outpatient laparoscopic gynecologic surgery.
    Graczyk SG; McKenzie R; Kallar S; Hickok CB; Melson T; Morrill B; Hahne WF; Brown RA
    Anesth Analg; 1997 Feb; 84(2):325-30. PubMed ID: 9024022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention and treatment of postoperative nausea and vomiting.
    Kovac AL
    Drugs; 2000 Feb; 59(2):213-43. PubMed ID: 10730546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P; D'Hollander A; Paxton L; Schoeffler P; Wessel P; Navé S; Brown RA; Hahne WF
    J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.
    Rojas C; Slusher BS
    Eur J Pharmacol; 2012 Jun; 684(1-3):1-7. PubMed ID: 22425650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
    Constenla M
    Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
    Perez EA
    Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pooled analysis of three large clinical trials to determine the optimal dose of dolasetron mesylate needed to prevent postoperative nausea and vomiting. The Dolasetron Prophylaxis Study Group.
    Philip BK; McLeskey CH; Chelly JE; McKenzie R; Kovac AL; Diemunsch P; DuBois DM
    J Clin Anesth; 2000 Feb; 12(1):1-8. PubMed ID: 10773500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
    Whitmore JB; Kris MG; Hesketh PJ; Grote TH; DuBois DM; Cramer MB; Hahne WF
    Support Care Cancer; 1998 Sep; 6(5):473-8. PubMed ID: 9773466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.